ASS1 and glioblastoma: The present study was carried out to investigate our hypothesis that metabolomic analysis, represented here by 1D and 2D GC-TOFMS combined with chemometric bioinformatics, can discriminate between ASS1 positive and ASS1 negative GBM cell lines and potentially identify metabolic biomarkers for the non-invasive detection of these subtypes and unveil additional novel targets for their treatment.